Action·LSE·£
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to identify and eradicate cancerous cells. The company currently oversees six ongoing Phase 2 clinical trials. Notably, its primary therapeutic candidate, lifileucel, is under investigation in two of these studies: C-144-01 for advanced melanoma and C-145-04 for cervical cancer that is recurrent, metastatic, or persistent. Furthermore, another candidate, LN-145, is being assessed in study C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics maintains strategic alliances and licensing arrangements with esteemed institutions including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Incorporated in 2007 and situated in San Carlos, California, the organization was formerly known as Lion Biotechnologies, Inc. until its rebranding in June 2017.
Voyez le prix de 0JDK.L en direct sur votre écran physique. Alertes via apps iOS et Android.
